Guangzhou Wondfo BiotechLtd (300482) Stock Overview
An in vitro diagnostics company, engages in the research and development, production, market, sale, and service of vitro diagnostic products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
300482 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Guangzhou Wondfo Biotech Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥20.04 |
| 52 Week High | CN¥26.48 |
| 52 Week Low | CN¥19.26 |
| Beta | 1.31 |
| 1 Month Change | -10.01% |
| 3 Month Change | -9.07% |
| 1 Year Change | -16.74% |
| 3 Year Change | -53.33% |
| 5 Year Change | -66.60% |
| Change since IPO | 307.06% |
Recent News & Updates
Recent updates
Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) Doing What It Can To Lift Shares
Feb 17
These 4 Measures Indicate That Guangzhou Wondfo BiotechLtd (SZSE:300482) Is Using Debt Safely
Jan 17Returns On Capital At Guangzhou Wondfo BiotechLtd (SZSE:300482) Paint A Concerning Picture
Nov 18Guangzhou Wondfo BiotechLtd's (SZSE:300482) Shareholders May Want To Dig Deeper Than Statutory Profit
Nov 01Cautious Investors Not Rewarding Guangzhou Wondfo Biotech Co.,Ltd's (SZSE:300482) Performance Completely
Sep 06Returns On Capital At Guangzhou Wondfo BiotechLtd (SZSE:300482) Paint A Concerning Picture
Jul 27Guangzhou Wondfo BiotechLtd's (SZSE:300482) Solid Earnings May Rest On Weak Foundations
Apr 29A Piece Of The Puzzle Missing From Guangzhou Wondfo Biotech Co.,Ltd's (SZSE:300482) Share Price
Mar 27There Are Reasons To Feel Uneasy About Guangzhou Wondfo BiotechLtd's (SZSE:300482) Returns On Capital
Feb 29Shareholder Returns
| 300482 | CN Medical Equipment | CN Market | |
|---|---|---|---|
| 7D | -3.7% | -2.0% | 0.3% |
| 1Y | -16.7% | -6.4% | 16.8% |
Return vs Industry: 300482 underperformed the CN Medical Equipment industry which returned -9.4% over the past year.
Return vs Market: 300482 underperformed the CN Market which returned 13.6% over the past year.
Price Volatility
| 300482 volatility | |
|---|---|
| 300482 Average Weekly Movement | 2.6% |
| Medical Equipment Industry Average Movement | 4.3% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in CN Market | 9.0% |
| 10% least volatile stocks in CN Market | 3.0% |
Stable Share Price: 300482 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300482's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 3,197 | Zhongxiong Peng | www.wondfo.com.cn |
Guangzhou Wondfo Biotech Co.,Ltd, an in vitro diagnostics company, engages in the research and development, production, market, sale, and service of vitro diagnostic products in China. The company offers rapid test kits for COVID-19, drug of abuse, tumor, infectious disease, fertility, tumor marker, and sexually transmitted diseases; immunofluorescence platform for detecting cardiac, thyroid, rheumatoid arthritis, sex hormone, anemia, gastroenterology, hypertension, thrombus, tumor, inflammation, diabetes, allergy, respiratory infection, kidney, brain injury, bone metabolism, and infectious disease; and chemiluminescence platform. It also provides semi-automatic blood coagulation analyzer and optical blood coagulation; automatic blood gas biochemical analyzer and blood gas analyzer; molecular diagnostics platform; fully automated pathology straining system; and fully automatic HbAlc analyzer.
Guangzhou Wondfo Biotech Co.,Ltd Fundamentals Summary
| 300482 fundamental statistics | |
|---|---|
| Market cap | CN¥9.31b |
| Earnings (TTM) | CN¥259.43m |
| Revenue (TTM) | CN¥2.57b |
Is 300482 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300482 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.57b |
| Cost of Revenue | CN¥980.78m |
| Gross Profit | CN¥1.59b |
| Other Expenses | CN¥1.33b |
| Earnings | CN¥259.43m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.56 |
| Gross Margin | 61.89% |
| Net Profit Margin | 10.08% |
| Debt/Equity Ratio | 10.5% |
How did 300482 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/12 00:25 |
| End of Day Share Price | 2025/12/12 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Guangzhou Wondfo Biotech Co.,Ltd is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shuo Song | Citic Securities Co., Ltd. |
| Binbin Zhang | Citic Securities Co., Ltd. |
| Yinglan Shu | Haitong International Research Limited |